# Prospective and Retrospective Observational Evaluation of Real World Outcome of Unfit AML Patients Treated With the Combination Venetoclax Plus Hypomethylating Agents, Under the Italian Law No.648/96

> **NCT04589728** · — · COMPLETED · sponsor: **Gruppo Italiano Malattie EMatologiche dell'Adulto** · enrollment: 202 (actual)

## Conditions studied

- Acute Myeloid Leukemia

## Interventions

- **DRUG:** Venetoclax plus HMA

## Key facts

- **NCT ID:** NCT04589728
- **Lead sponsor:** Gruppo Italiano Malattie EMatologiche dell'Adulto
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2021-02-23
- **Primary completion:** 2024-09-08
- **Final completion:** 2024-09-08
- **Target enrollment:** 202 (ACTUAL)
- **Last updated:** 2025-07-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04589728

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04589728, "Prospective and Retrospective Observational Evaluation of Real World Outcome of Unfit AML Patients Treated With the Combination Venetoclax Plus Hypomethylating Agents, Under the Italian Law No.648/96". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT04589728. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*